On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares rose in extended-hours trading on Monday after a panel of independent ...

Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...

, opens new tab late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly (LLY.N) , opens new tab executive said on Monday. The pill is part of a class ...

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on ...

As Google (GOOG, GOOGL) pivots to incorporate AI technology across its array of services, its parent company, Alphabet, is bringing on a new CFO. Anat Ashkenazi, a 23-year veteran of the ...

A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the ...

Alphabet Inc. named Eli Lilly & Co. executive Anat Ashkenazi as its new chief financial officer, replacing Ruth Porat who announced last year she planned to step down. Ashkenazi, 51, has served as ...

On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares. The ...